Annovis Bio Inc
NYSE:ANVS
Annovis Bio Inc
NYSE:ANVS
Price:
5.45 USD
-10.8%
Market Closed
Updated:
May 3, 2024
Annovis Bio Inc
Cash from Financing Activities
|
Annovis Bio Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Annovis Bio Inc
NYSE:ANVS
|
Cash from Financing Activities
$17.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
133%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Annovis Bio Inc's Cash from Financing Activities?
Cash from Financing Activities
17.3m
USD
17.3m
USD
Based on the financial report for Dec 31, 2023, Annovis Bio Inc's Cash from Financing Activities amounts to 17.3m USD.
What is Annovis Bio Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
133%
133%
The average annual Cash from Financing Activities growth rates for Annovis Bio Inc have been 13% over the past three years , 133% over the past five years .
You don't have any saved screeners yet
